Meeting
2020 Gastrointestinal Cancers Symposium
Immune modulation after Toca 511 and Toca FC treatment of colorectal cancer patients.
Authors
Gerald Steven Falchook
Sarah Cannon Research Institute, Denver, CO
Gerald Steven Falchook , Jordi Rodon Ahnert , Shree Venkat , Arthur Donahue , Peder Horner , Amber Thomassen , William Accomando , Maria Rodriguez-Aguirre , Cornelia Bentley , Daniel Hogan , Derek Ostertag , Sharon Yavrom , Thian Kheoh , Douglas J. Jolly , Harry E. Gruber , Jolene Shorr , Jaime R. Merchan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
NCT02576665
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 186)
Abstract #
186
Poster Bd #
J6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Reconstructing the tumor microenvironment to unlock therapeutic options in pancreatic cancer.
First Author: Ben George
Poster
2023 ASCO Annual Meeting
Variation in FOLFOX, FOLFIRI, and FOLFOXIRI effects on CD8+ T cell and PDL1 levels in MSS CRC patients.
First Author: Lindsey Carlsen
Poster
2023 ASCO Annual Meeting
A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.
First Author: Miguel Angel Villalona-Calero
Poster
2023 ASCO Genitourinary Cancers Symposium
Association of liver metastases, tumor microenvironment, and treatment outcomes in patients with urothelial bladder cancer treated with tislelizumab.
First Author: Linlin Xu